Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

RIGL

Rigel Pharmaceuticals

Dec 11 • 04:00PM ET

19.53

Dollar change -1.03
Percentage change -5.01	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD INCY NVAX VKTX ARWR ACAD ENTA KURA AMRN ANAB

| Held by: DWAS IWM VTI VXF IWO VTWO IWC IWN RSSL VTWG

Scroll to Statements

Index	RUT	P/E	90.17	EPS (ttm)	0.22	Insider Own	1.98%	Shs Outstand	17.61M	Perf Week	-26.27%
Market Cap	344.03M	Forward P/E	19.99	EPS next Y	0.98	Insider Trans	0.00%	Shs Float	17.27M	Perf Month	-21.72%
Income	3.88M	PEG	-	EPS next Q	0.30	Inst Own	67.84%	Short Float	2.73%	Perf Quarter	50.81%
Sales	157.47M	P/S	2.18	EPS this Y	120.53%	Inst Trans	18.15%	Short Ratio	2.17	Perf Half Y	95.30%
Book/sh	-0.83	P/B	-	EPS next Y	240.01%	ROA	3.05%	Short Interest	0.47M	Perf Year	52.58%
Cash/sh	3.47	P/C	5.63	EPS next 5Y	-	ROE	-	52W Range	7.48 - 29.82	Perf YTD	34.69%
Dividend Est.	-	P/FCF	32.09	EPS past 5Y	19.96%	ROI	8.60%	52W High	-34.51%	Beta	1.24
Dividend TTM	-	Quick Ratio	1.81	Sales past 5Y	26.32%	Gross Margin	89.43%	52W Low	160.95%	ATR (14)	1.79
Dividend Ex-Date	-	Current Ratio	1.96	EPS Y/Y TTM	115.56%	Oper. Margin	6.03%	RSI (14)	36.73	Volatility	8.75% 8.23%
Employees	147	Debt/Eq	-	Sales Y/Y TTM	18.97%	Profit Margin	2.46%	Recom	2.33	Target Price	31.33
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	315.62%	Payout	-	Rel Volume	1.00	Prev Close	20.56
Sales Surprise	31.89%	EPS Surprise	1096.58%	Sales Q/Q	96.58%	Earnings	Nov 07 AMC	Avg Volume	217.52K	Price	19.53
SMA20	-22.59%	SMA50	-0.72%	SMA200	42.88%	Trades		Volume	218,305	Change	-5.01%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-23	Resumed	Piper Sandler	Neutral	$2
Jun-09-22	Downgrade	Citigroup	Buy → Neutral
Jun-08-22	Downgrade	Piper Sandler	Overweight → Neutral	$7 → $1
Jun-08-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$6 → $1
Mar-23-22	Initiated	B. Riley Securities	Neutral	$4
Nov-09-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-15-19	Resumed	Cantor Fitzgerald	Overweight	$7 → $5
Sep-26-19	Resumed	JP Morgan	Overweight	$7
Mar-01-19	Reiterated	Cantor Fitzgerald	Overweight	$9 → $7
Aug-27-18	Initiated	Citigroup	Buy	$8.50
May-02-18	Reiterated	Cantor Fitzgerald	Overweight	$6 → $9
Dec-21-17	Resumed	Piper Jaffray	Overweight	$6
Dec-15-17	Initiated	Cantor Fitzgerald	Overweight	$6
Nov-06-17	Resumed	H.C. Wainwright	Buy	$7
Mar-09-17	Reiterated	H.C. Wainwright	Buy	$6 → $5
Aug-31-16	Reiterated	H.C. Wainwright	Buy	$6 → $7
Aug-30-16	Reiterated	Piper Jaffray	Overweight	$10 → $11
Jul-13-16	Initiated	H.C. Wainwright	Buy	$6
Jun-13-16	Initiated	Piper Jaffray	Overweight
Apr-22-16	Upgrade	JP Morgan	Neutral → Overweight

Show Previous Ratings

Dec-09-24 12:02PM	Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition (PR Newswire) -9.00%
Dec-02-24 08:05AM	Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS (PR Newswire)
Nov-19-24 09:55AM	How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28% (Zacks) +5.15%
Nov-12-24 08:05AM	Rigel to Present at the Jefferies London Healthcare Conference (PR Newswire) +9.10%
Nov-08-24 09:48AM	Q3 2024 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +42.94%
02:27AM	Loading…
02:27AM	Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Nov-07-24 05:15PM	Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates (Zacks)
04:09PM	Rigel: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Nov-06-24 07:42AM	Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-05-24 09:05AM	Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition (PR Newswire)
Oct-31-24 08:05AM	Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update (PR Newswire)
Oct-24-24 04:35PM	Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO (pralsetinib) (PR Newswire)
Oct-16-24 10:00AM	Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE (GlobeNewswire)
Oct-04-24 08:05AM	Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
04:34AM	Loading…
Sep-25-24 04:34AM	Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains? (Zacks)
Sep-12-24 08:05AM	Rigel to Present at the 2024 Cantor Global Healthcare Conference (PR Newswire)
Sep-06-24 06:32AM	Rigel enrols first participant in Phase Ib/II AML treatment regimen trial (Clinical Trials Arena)
Sep-05-24 07:30AM	Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA (olutasidenib) in mIDH1 AML (PR Newswire)
Sep-03-24 08:00AM	Rigel Expands Relationship with Kissei to include REZLIDHIA (olutasidenib) in Japan, the Republic of Korea and Taiwan (PR Newswire)
Aug-29-24 08:05AM	Rigel to Participate in Upcoming September Investor Conferences (PR Newswire) +5.04%
Aug-07-24 11:12AM	Q2 2024 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +5.79%
Aug-06-24 05:30PM	Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.02%
04:25PM	Rigel: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Jul-30-24 10:01AM	Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:05AM	Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update (PR Newswire)
Jul-12-24 08:05AM	Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jun-25-24 08:00AM	Rigel Announces Reverse Stock Split (PR Newswire) -11.87%
Jun-24-24 04:05PM	Rigel Pharmaceuticals Completes Transfer of GAVRETO (pralsetinib) New Drug Application (PR Newswire)
09:36AM	Loading…
Jun-17-24 09:36AM	Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues (InvestorPlace)
Jun-14-24 03:05AM	Rigel Announces Five Presentations at the EHA2024 Hybrid Congress (PR Newswire)
Jun-03-24 08:13AM	Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting (PR Newswire)
May-30-24 08:05AM	Rigel to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-23-24 05:00PM	Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress (PR Newswire)
May-10-24 12:00PM	Rigel (RIGL) Upgraded to Buy: Here's What You Should Know (Zacks)
May-08-24 12:47PM	Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2024 Earnings Call Transcript (Insider Monkey) -16.61%
03:49AM	Rigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves ... (GuruFocus.com)
May-07-24 09:00PM	RIGL Stock Earnings: Rigel Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:50PM	Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:47PM	Rigel: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports First Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Apr-30-24 10:01AM	Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:05AM	Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update (PR Newswire)
Apr-10-24 04:30PM	Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Apr-04-24 08:05AM	Rigel Announces Publication of Data on REZLIDHIA (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma (PR Newswire)
Mar-12-24 08:05AM	Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer (PR Newswire)
Mar-07-24 01:50PM	Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year (GuruFocus.com)
11:59AM	Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 11:53AM	Q4 2023 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +5.41%
Mar-05-24 08:51PM	RIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023 (InvestorPlace)
05:10PM	Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4 (Zacks)
04:01PM	Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (PR Newswire)
Feb-27-24 08:05AM	Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update (PR Newswire) +5.63%
Feb-22-24 07:50AM	Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO (PR Newswire) +16.07%
Feb-19-24 08:34AM	Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates? (Zacks)
Jan-10-24 08:00AM	Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board (GlobeNewswire)
Jan-08-24 08:54AM	Rigel Pharmaceuticals Expects 2023 Net Product Sales To Rise 36% - Quick Facts (RTT News) +7.25%
08:05AM	Rigel Pharmaceuticals Provides Business Update (PR Newswire)
Jan-05-24 04:30PM	Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -7.38%
Jan-04-24 08:05AM	Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma (PR Newswire)
Jan-03-24 10:51AM	Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now (Zacks)
08:05AM	Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-08-23 08:05AM	Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA (Olutasidenib) in AML and Other Cancers (PR Newswire) +16.23%
Nov-08-23 03:09PM	Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 05:06PM	Rigel Pharmaceuticals Inc (RIGL) Reports Q3 2023 Financial Results: A Step Towards Financial ... (GuruFocus.com)
04:30PM	Rigel: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-06-23 08:05AM	Rigel to Present at the Jefferies London Healthcare Conference (PR Newswire)
Nov-02-23 09:27AM	Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (PR Newswire)
Oct-31-23 08:05AM	Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update (PR Newswire)
Oct-11-23 08:05AM	Rigel Announces Presentation at the Upcoming IDWeek 2023 (PR Newswire)
Oct-06-23 04:30PM	Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-20-23 08:05AM	Rigel to Present at the 2023 Cantor Global Healthcare Conference (PR Newswire)
Aug-30-23 08:05AM	Rigel to Participate in Upcoming September Investor Conferences (PR Newswire)
Aug-02-23 10:16AM	Q2 2023 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-01-23 05:15PM	Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:08PM	Rigel: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Jul-27-23 06:06PM	3 Stocks to Buy for Lottery Jackpot Style Returns (InvestorPlace)
Jul-25-23 08:00AM	Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update (PR Newswire)
Jul-05-23 04:30PM	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) +5.34%
06:58AM	Investors in Rigel Pharmaceuticals (NASDAQ:RIGL) have unfortunately lost 55% over the last five years (Simply Wall St.)
Jun-07-23 01:41PM	Bullish Rigel Pharmaceuticals Insiders Rewarded As Their Investment Rises To US$1.5m \ (Simply Wall St.)
08:05AM	Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML (PR Newswire)
Jun-06-23 08:05AM	Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances (PR Newswire) +7.09%
Jun-01-23 08:05AM	Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting (PR Newswire)
May-31-23 08:05AM	Rigel to Present at the Jefferies 2023 Global Healthcare Conference (PR Newswire)
May-25-23 06:07AM	3 Penny Stocks to Make You the Millionaire Next Door (InvestorPlace)
May-10-23 03:31PM	7 Growth Stocks That Are Too Cheap to Ignore Right Now (InvestorPlace)
May-04-23 10:06AM	Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-03-23 10:39AM	Q1 2023 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-02-23 05:15PM	Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Rigel: Q1 Earnings Snapshot (AP Finance)
04:01PM	Rigel Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Apr-26-23 10:02AM	Earnings Preview: Pacira (PCRX) Q1 Earnings Expected to Decline (Zacks)
Apr-25-23 10:01AM	Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:05AM	Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update (PR Newswire)
Apr-21-23 09:27AM	Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is favoured by institutional owners who hold 55% of the company (Simply Wall St.)
Apr-16-23 09:30AM	12 Best Low-Priced Growth Stocks To Buy (Insider Monkey)

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Santos David A	EVP, Chief Commercial Officer	Feb 05 '24	Sale	1.14	8,918	10,167	349,093	Feb 06 08:18 PM
Santos David A	EVP, Chief Commercial Officer	Feb 02 '24	Sale	1.13	5,601	6,329	358,011	Feb 06 08:18 PM
Schorno Dean L	EVP & Chief Financial Officer	Feb 05 '24	Sale	1.14	7,027	8,011	402,891	Feb 06 08:18 PM
Schorno Dean L	EVP & Chief Financial Officer	Feb 02 '24	Sale	1.13	5,601	6,327	409,918	Feb 06 08:18 PM
RODRIGUEZ RAUL R	CEO, President	Feb 05 '24	Sale	1.14	30,545	34,821	2,036,629	Feb 06 08:18 PM
RODRIGUEZ RAUL R	CEO, President	Feb 02 '24	Sale	1.13	22,349	25,261	2,067,174	Feb 06 08:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RIGL

Rigel Pharmaceuticals

Upgrade your FINVIZ experience